Mylanta One Antacid/anti-gas Tablet, Chewable
NDC Package 62372-552-51
Package Information
Mylanta One Antacid/anti-gas (calcium carbonate, magnesium hydroxide, dimethicone) tablets is ▪adults and children 12 years and over: chew 1 tablet as symptoms occur, or as directed by doctor▪do not take more than 6 tablets in 24 hours▪do not use the maximum dosage for more than 2 weeks▪children under 12 years of age: ask a doctor. This formulation utilizes a tablet, chewable delivery system. Marketed by Infirst Healthcare Inc., this product is identified by NDC 62372-552 and is authorized under FDA application M001.
Identification & Billing
- RxCUI: 2556794 - calcium carbonate 1000 MG / magnesium hydroxide 270 MG / dimethicone 80 MG Chewable Tablet
- RxCUI: 2556794 - calcium carbonate 1000 MG / magnesium hydroxide 270 MG / simethicone 80 MG Chewable Tablet
Clinical Specifications
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Skin Barrier Activity - [PE] (Physiologic Effect)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 62372 - Infirst Healthcare Inc.
- 62372-552 - Mylanta One Antacid/anti-gas
- 62372-552-51 - 50 TABLET, CHEWABLE in 1 BOTTLE
- 62372-552 - Mylanta One Antacid/anti-gas
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (62372-552). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62372-552-51 identifies a specific commercial package of 50 tablet, chewable in 1 bottle of Mylanta One Antacid/anti-gas, a human over the counter drug labeled by Infirst Healthcare Inc.. This tablet, chewable is formulated for oral use and contains calcium carbonate; dimethicone; magnesium hydroxide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Infirst Healthcare Inc. on May 04, 2021. The current certification is valid through December 31, 2026.
How is this Infirst Healthcare Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62372055251. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.